What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors?

Bicara Therapeutics CEO Claire Mazumdar sold 15,000 shares worth approximately $301,000 on May 18, 2026, through a pre-arranged Rule 10b5-1 trading plan adopted in February 2025. The sale reduced her direct holdings by 4%, but she retains 362,152 shares and 146,107 options, indicating continued substantial alignment with the company. The transaction appears routine for liquidity purposes rather than a sign of concern about the company's outlook.

06/13/2026, 1:01 AM • The Motley Fool

Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Bicara Therapeutics (NASDAQ: BCAX) successfully closed an oversubscribed public offering, raising approximately $172.5 million in gross proceeds through the sale of 8,581,250 common shares and 2,200,000 pre-funded warrants. The underwriters fully exercised their option to purchase additional shares. The company plans to use the proceeds to advance its lead program ficerafusp alfa, a first-in-class bifunctional antibody for solid tumors, including regulatory filing and commercial launch preparations, manufacturing costs, and clinical development acceleration.

02/26/2026, 4:01 PM • Benzinga

Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants

Bicara Therapeutics priced a $150 million underwritten public offering of 7.175 million common shares at $16.00 per share and 2.2 million pre-funded warrants. The company plans to use proceeds to advance its lead candidate ficerafusp alfa, build commercial infrastructure, accelerate development in head and neck cancer, and fund manufacturing and expansion efforts. The offering is expected to close on February 26, 2026.

02/24/2026, 11:13 PM • GlobeNewswire

Bicara Therapeutics Announces Proposed Public Offering of Common Stock

Bicara Therapeutics (NASDAQ: BCAX), a clinical-stage biopharmaceutical company, announced a proposed underwritten public offering of $150 million in common stock with a 30-day option for underwriters to purchase an additional $22.5 million. The company plans to use proceeds to advance its lead drug ficerafusp alfa, build commercial infrastructure, and support regulatory filings and commercial launch efforts.

02/24/2026, 4:01 PM • Benzinga

Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12

Bicara Therapeutics will present at the J.P. Morgan 2026 Healthcare Conference, highlighting its lead program ficerafusp alfa, a bifunctional antibody designed to treat solid tumor cancers by targeting EGFR and TGF-β.

12/15/2025, 8:00 AM • GlobeNewswire

Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026

Bicara Therapeutics reported promising Phase 1b data for ficerafusp alfa, a bifunctional antibody, in treating HPV-negative head and neck squamous cell carcinoma. The 750mg weekly dose showed a 57% confirmed overall response rate and was well-tolerated when combined with pembrolizumab.

12/06/2025, 8:00 AM • GlobeNewswire

Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology

Oncology drug delivery is advancing through nanomedicine technologies, with companies developing innovative platforms to improve drug bioavailability, reduce toxicity, and enhance therapeutic effectiveness in cancer treatments.

10/27/2025, 8:30 AM • Benzinga